Valion Bio, Inc.
Valion Bio, Inc. is a U.S.-based biomedical company developing recombinant biologic and bioelectronic therapies, with a core focus on its TLR5 program and the Entolimod™ family of candidates. The company also operates Velocity Bioworks, a San Antonio, Texas CDMO platform that supports biomanufacturing and related development services.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueRecombinant biologic candidates centered on the TLR5 platform, including Entolimod and Entolasta.
Product candidates derived from vagus nerve stimulation research and development.
ClearUP and related accessories sold through direct and reseller channels.
Full-service CDMO activities provided through Velocity Bioworks in San Antonio.
Customers
Valion serves two very different customer bases: consumers and channel partners for ClearUP, and future patients, physicians, and institutional buyers for its therapeutic pipeline. Its CDMO operations are aimed at external biopharma clients that need specialized development and manufacturing support. The company’s therapeutic programs also depend on regulators, clinical investigators, and government or defense-related stakeholders for development and approval pathways.
Individuals purchasing ClearUP directly or through online retail channels for personal use.
Channel partners such as Simply Medical, Cardinal Health, and other resellers that stock and distribute ClearUP.
External customers that may use Velocity Bioworks for specialized biomanufacturing and development services.
Hospitals, physicians, and other institutional buyers that could use future Entolimod or Entolasta therapies.
Strategy
Valion’s strategy is to shift from consumer device monetization toward biologic and bioelectronic drug development with longer-duration commercial potential. It is also building manufacturing control through Velocity Bioworks so it can support Entolimod supply, accelerate development, and potentially generate third-party CDMO revenue. The company is pursuing regulatory advancement, clinical development, and selective licensing or transaction opportunities to support its pipeline.
Clinical progress is the main path to durable value creation beyond the legacy consumer device business.
Direct control of biomanufacturing can improve execution, supply reliability, and commercialization readiness.
External manufacturing services can diversify revenue while the therapeutic pipeline matures.
The consumer device business is being wound down, so monetization or divestiture can free capital for the pipeline.
Geography
Valion is headquartered in the United States and conducts its consumer and development activities primarily from U.S. operations. Its manufacturing footprint includes San Antonio, Texas through Velocity Bioworks, which is intended to support both internal pipeline programs and external CDMO work. The company’s commercial exposure is therefore concentrated in the U.S., while future therapeutic commercialization could extend into regulated global markets.
Risks
Valion faces development-stage biotech risk, including clinical failure, regulatory delay, and manufacturing scale-up challenges for its therapeutic candidates. The company also has concentrated exposure to the wind-down of ClearUP, dependence on external financing, and execution risk in building a CDMO business that must compete on quality, reliability, and compliance.
- Financing riskImpact: CriticalLikelihood: High
The company has relied on equity and other financing and may need more capital before product revenue scales.
Exposure: Operating runway and trial funding
- Regulatory delay or rejectionImpact: HighLikelihood: High
Therapeutic candidates require FDA review, and timelines can shift materially with data or filing issues.
Exposure - Clinical development failureImpact: HighLikelihood: Medium
Entolimod, Entolasta, and bioelectronic candidates may not demonstrate safety or efficacy in trials.
Exposure: Pipeline value and future commercialization
- Consumer business wind-downImpact: MediumLikelihood: High
Exiting ClearUP can reduce near-term revenue and create transition risk in channel inventory sell-through.
Exposure: Legacy consumer sales
- Manufacturing and CDMO executionImpact: MediumLikelihood: High
Biomanufacturing requires strict quality systems, regulatory compliance, and reliable customer delivery.
Exposure: Velocity Bioworks operations
Accounting
Judgemental itemsClearUP is a physical product, so excess or obsolete inventory can require write-downs.
Impact: Affects cost of sales and gross margin
Consumer and reseller sales require estimates for returns and allowances.
Impact: Affects reported net revenue
Early-stage public companies often use equity awards to conserve cash.
Impact: Affects operating expenses and loss measures
Funding sufficiency influences disclosure and the timing of planned activities.
Impact: Affects financial statement presentation and risk disclosure
Similar listed companies
Publicly listed companies with a comparable business focus.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Elutia, Inc
ELUT · Biological Products, (No Diagnostic Substances)
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Aethlon Medical, Inc
AEMD · Surgical & Medical Instruments & Apparatus
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Last updated: 24/09/2026